This study elucidates the synergistic mechanism between the IL-17A and IL-36 pathways in hidradenitis suppurativa, providing critical experimental design insights for developing bispecific antibodies targeting refractory tunnel lesions and constructing humanized mouse models.
Literature Overview
The article "Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody," published in Signal Transduction and Targeted Therapy, systematically explores the unique molecular mechanism by which the IL-17A and IL-36 signaling axis synergistically drives tunnel formation in hidradenitis suppurativa (HS). It also validates the superior efficacy of the bispecific antibody HB0043 in preclinical and early clinical trials.Background Knowledge
Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disease. A core clinical challenge lies in deep tunnel lesions that are resistant to existing single-target biologics (such as anti-TNF-α or anti-IL-17A agents). Current bottlenecks in target research stem from the failure to resolve the spatial interaction network between epithelial cells and immune stromal cells within the tunnel microenvironment, resulting in the inability of single-pathway blockade to completely eliminate inflammatory loops. This study leverages integrated multi-omics analysis (scRNA-seq, spatial transcriptomics, and plasma proteomics) to precisely identify a unique migratory spinous keratinocyte subpopulation within tunnels. These cells were found to activate neutrophils and inflammatory fibroblasts through the synergistic action of IL-36γ and IL-17A, forming a self-amplifying pathogenic hub. This discovery lays the theoretical foundation for developing cross-pathway bispecific blockade strategies.
Research Methods and Core Experiments
The authors first employed single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST-seq) to generate high-resolution maps of lesion tissues from 11 HS patients and healthy controls, identifying disease-related immune and stromal cell subpopulations. Key evidence showed that IL-36γ and IL-17A exhibited spatial co-enrichment in tunnel epithelial cells, and in vitro experiments confirmed that their synergistic stimulation promoted keratinocyte proliferation and inflammatory cytokine expression. Subsequently, the research team developed the bispecific antibody HB0043, targeting both IL-17A and IL-36R. Using IL-36R as a positioning anchor, the neutralization effect on IL-17A was enriched at the lesion site. In preclinical experiments, HB0043 significantly outperformed parental monoclonal antibodies and IL-17A/IL-17F bispecific antibodies in inhibiting inflammatory responses. Furthermore, a proof-of-concept clinical trial (NCT06895499) was conducted, enrolling 15 patients with severe hidradenitis suppurativa (Hurley Stage III). High-frequency ultrasound was used to assess tunnel regression, combined with longitudinal plasma proteomic analysis to evaluate changes in systemic inflammation and metabolic status.Key Conclusions and Perspectives
Research Significance and Prospects
This discovery offers a new paradigm for drug development: addressing complex inflammatory diseases requires cross-pathway bispecific strategies to dismantle synergistic pathogenic networks, rather than simply blocking single nodes. In terms of clinical monitoring, the multi-omics dynamic tracking method proposed in this study (combining local tissue changes with systemic proteomics) can serve as a novel biomarker system for evaluating the efficacy of refractory skin diseases. Additionally, this study reveals specific cell interaction circuits in hidradenitis suppurativa, providing clear target combinations and validation criteria for future construction of more precise disease models (such as humanized mouse models or organoid models) to screen for novel bispecific antibodies.
Conclusion
Through integrated multi-omics analysis, this study successfully decoded the IL-17A and IL-36 synergistically driven pathogenic hub in hidradenitis suppurativa, breaking through the bottleneck of traditional single-target therapies in deep tunnel lesions. The clinical validation of the HB0043 bispecific antibody not only confirmed the efficacy of the dual-blockade strategy in inducing anatomical structural repair but also set a new milestone for the treatment of refractory autoimmune skin diseases. From laboratory mechanism elucidation to clinical translation, this study emphasizes the central role of the spatial microenvironment in disease pathogenesis, suggesting that future drug development should focus on disrupting complex cell interaction networks. This achievement not only brings hope for structural healing to patients with hidradenitis suppurativa but also provides a referenceable precision treatment framework for other chronic inflammatory diseases with similar inflammatory loops, marking a significant leap in biologic development from single-point blockade to network regulation.
